RE: Covid-19 Therapeutics Still Matter, Even with Vaccines14 Feb 2021 02:37
Ferrari- thanks for your post.
That is a pretty comprehensive report which concentrates the necessity for access to early stage treatments to all but particularly for Low and Middle Income Countries. It seems that probable that cheap tablets are going to be the only way high availability of treatments will be available to these countries and I expect that Synairgen would be too costly and complicated to administer to be seriously effective.
There are a couple of potential treatments mentioned in the report currently undergoing trials which may be competitors to Synairgen.
The lack of funding for Global treatments is mentioned below. At present Dex is available but some hospitals don't have enough oxygen so that is going to be less effective in those instances.
The report suggests that Global funding will seek to provide mAbs worldwide and therefore potentially SNG-001 could be funded similarly. I expect this is an unachievable aim in the foreseeable future and in any event once approved I expect near term production SNG will be fully taken up by USA, UK and EU.
'The immediate need that the therapeutics pillar is addressing is finding drugs for LMICs, with a focus on
marginalised communities. “It is analysing over 1,700 clinical trials for promising treatments and has
secured dexamethasone for up to 2.9 million patients in low-income countries. The Global Fund and
UNICEF are the institutions that are actually procuring dexamethasone for LMICs. Access to
dexamethasone has been expedited through an emergency use listing (EUL) procedure, publication of
treatment guidelines, and the creation of a stockpile for emergency use.” 105 It has also secured an
agreement to help facilitate future access to monoclonal antibody therapies in low- and middle-income
countries.
The main constraint – as far as can be determined from publicly available documents – is funding. The
total committed is just over $6 billion – but an additional $3.5 billion is needed urgently. For 2021, the
funding gap is $23.7 billion if tools are to be deployed across the world as they become available. These
numbers are not disaggregated, so do not take specific account of the funding gap for treatments alone.
However, public statements on promising therapies made by Dr Nick Cammack, head of the Wellcome
Trust's Covid-19 Therapeutic Accelerator project, are suggestive. In statements made on 7 October
2020, he argued that there needs to be more “global funding and the engagement of large and small
companies” in this space, highlighting that £1.5 billion has been pumped into the race for a vaccine, while
only £232 million has been invested in the research and development of treatments.'
Cont. below
Spinnaker
Sign In
Follow the stocks
